Sign In to Request a Protocol
Sign In to Request a Protocol

TB-500 (5 mg Vial)

  • Table of Contents

TB-500 (5 mg Vial)

TB-500 is dosed at 500 mcg–1 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
  • Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
  • Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze the reconstituted solution.
TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in tissue repair and regeneration. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for accurate insulin syringe measurements in research settings.
  • Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

PhaseDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2500 mcg30 units (0.30 mL)
Weeks 3–4600 mcg36 units (0.36 mL)
Weeks 5–8750 mcg45 units (0.45 mL)
Weeks 9–121000 mcg60 units (0.60 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units ≥30 for excellent measurement accuracy.

Total weekly dose averages ~5 mg, which is consistent with commonly cited research protocols.

Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label with the date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. TB‑500 is not FDA‑approved for human use and is for research purposes only.

  • Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (TB-500, 5 mg each):
  • 8 weeks: 8 vials
  • 12 weeks: 12 vials
  • 16 weeks: 16 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use approximately 3.0 mL per vial for reconstitution.
  • 8 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • 12 weeks (12 vials): 36 mL → 4 × 10 mL bottles
  • 16 weeks (16 vials): 48 mL → 5 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
  • Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of the reconstituted solution.
  • Dosing Protocol

Suggested daily titration approach.

  • Start: 500 mcg daily; increase by approximately 100–150 mcg every 2 weeks as tolerated.
  • Target: 750–1000 mcg daily by Weeks 5–12.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks based on the research protocol.
  • Timing: Any consistent time each day; rotate injection sites systematically.
  • Storage Instructions

Proper storage preserves peptide quality and activity.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze the reconstituted solution, as freezing can denature peptides.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Use reconstituted vials within 28 days when stored with bacteriostatic water preservative.
  • Important Notes

Practical considerations for consistency and safety in research protocols.

  • Use a new sterile insulin syringe for each injection; dispose of it in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy.
  • Inject slowly; wait a few seconds before withdrawing the needle to help prevent backflow.
  • Document the daily dose, injection site, and any observations to maintain consistency.
  • Regulatory Note: TB-500 is banned by WADA for athletic use and is not FDA-approved for human administration.
  • How This Works
TB-500 represents the N-terminal active fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for the actin-binding and cell-migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments. Recent metabolic studies suggest TB-500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity.
  • Potential Benefits & Side Effects

Observations from preclinical and veterinary literature.

  • Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration.
  • May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models.
  • Generally well tolerated in veterinary studies; occasional mild injection-site reactions (redness, tenderness) have been reported.
  • Human safety data is limited; no large-scale clinical trials have been completed specifically for TB-500.
  • Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Pair with a balanced, protein-forward diet tailored to individual energy needs.
  • Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
  • Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
  • Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
  • Injection Technique
General subcutaneous guidance from clinical best‑practice resources
  • Clean the vial stopper and skin with alcohol; allow to air dry completely.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
  • Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.
  • Recommended Source
We recommend Vitality Labs Blueprint Peptides for high‑purity TB‑500 (5 mg).

Why Vitality Labs Blueprint Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. TB‑500 is not approved by the FDA for human use and is for research purposes only. TB‑500 is a prohibited substance in competitive sports under WADA regulations.
  • References

FASEB Journal

— Biological activities of thymosin β4 defined by active peptide sequences (TB‑500 fragment identification)
More Info

Journal of Chromatography A (PubMed)

— Doping control analysis of TB‑500 as synthetic thymosin β4 fragment in biological samples
More Info

WADA Scientific Research

— Investigation of TB‑500 metabolism, synthesis of metabolites, and detection limits
More Info

Racing Medication & Testing Consortium

— Thymosin β4 regulatory bulletin (TB‑500 use in equine sports medicine)
More Info

Journal of Investigative Dermatology (PubMed)

— Thymosin beta4 accelerates wound healing (preclinical wound healing model)
More Info

FASEB Journal (PubMed)

— Active site mapping of thymosin β4 fragments for angiogenesis and cell migration
More Info

Verified Peptides Storage Guide

— Lyophilized peptide storage best practices (temperature, humidity, light protection)
More Info

Empower Pharmacy

— Bacteriostatic water injection guidelines (0.9% benzyl alcohol, multi‑dose vial stability)
More Info

NCBI Bookshelf

—  Best practices for subcutaneous injection (aseptic technique, site rotation)

More Info

WADA Prohibited List

— TB‑500 classification as prohibited substance in competitive sports

More Info

Journal of Investigative Dermatology

— Thymosin β4 wound healing mechanisms (collagen deposition, angiogenesis, granulation tissue)
More Info

Journal of Chromatography B (PubMed)

— Quantification of TB‑500 metabolites and wound healing activity screening (prodrug hypothesis)
More Info

CenterWatch Clinical Trials

— Clinical trial registry for thymosin β4 in acute myocardial infarction (no TB‑500 specific trials)
More Info

Nursing Journal (LWW)

— How to administer subcutaneous injections (clinical technique guidelines)
More Info

University of Michigan Health

— Patient education guide for subcutaneous injection technique

More Info

Vitality Lab Peptides

TB‑500 (5 mg) product page (purity specifications and batch documentation)

More Info